JP5225074B2 - Ｇｌｐ−１ｐｅｇ化化合物 - Google Patents

Ｇｌｐ−１ｐｅｇ化化合物 Download PDF

Info

Publication number: JP5225074B2
Authority: JP; Japan
Prior art keywords: glp; xaa; pegylated; compound; cys
Prior art date: 2005-05-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2008511371A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008540565A5 (2

JP2008540565A (ja

Inventor

ヴォルフガング・グレースナー

ジョン・フィリップ・マイヤー

ローン・リー・ミリカン・ジュニア

アンドリュー・マーク・ビック

リアンシャン・チャン

Original Assignee

イーライリリーアンドカンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-13

Filing date

2006-05-11

Publication date

2013-07-03

2006-05-11 Application filed by イーライリリーアンドカンパニー filed Critical イーライリリーアンドカンパニー

2008-11-20 Publication of JP2008540565A publication Critical patent/JP2008540565A/ja

2009-06-25 Publication of JP2008540565A5 publication Critical patent/JP2008540565A5/ja

2013-07-03 Application granted granted Critical

2013-07-03 Publication of JP5225074B2 publication Critical patent/JP5225074B2/ja

2026-05-11 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 69
150000001875 compounds Chemical class 0.000 title claims description 21
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title claims 14
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title claims 14
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 53
-1 GLP-1 compound Chemical class 0.000 claims description 61
230000006320 pegylation Effects 0.000 claims description 24
238000006243 chemical reaction Methods 0.000 claims description 10
150000001413 amino acids Chemical group 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 7
208000008589 Obesity Diseases 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
WQUWKZJWBCOHQH-UHFFFAOYSA-N 1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]pyrrole-2,5-dione Chemical compound COCCOCCOCCN1C(=O)C=CC1=O WQUWKZJWBCOHQH-UHFFFAOYSA-N 0.000 claims description 3
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000002202 Polyethylene glycol Substances 0.000 abstract description 45
108090000765 processed proteins & peptides Proteins 0.000 abstract description 25
210000004369 blood Anatomy 0.000 abstract description 14
239000008280 blood Substances 0.000 abstract description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 13
239000008103 glucose Substances 0.000 abstract description 12
230000003247 decreasing effect Effects 0.000 abstract description 5
230000030135 gastric motility Effects 0.000 abstract description 5
230000008991 intestinal motility Effects 0.000 abstract description 5
235000012631 food intake Nutrition 0.000 abstract description 3
230000002496 gastric effect Effects 0.000 abstract description 3
239000000203 mixture Substances 0.000 abstract description 3
230000037406 food intake Effects 0.000 abstract description 2
230000000968 intestinal effect Effects 0.000 abstract description 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 82
102100040918 Pro-glucagon Human genes 0.000 description 74
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
238000000034 method Methods 0.000 description 14
238000000338 in vitro Methods 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
230000000694 effects Effects 0.000 description 11
230000008030 elimination Effects 0.000 description 11
238000003379 elimination reaction Methods 0.000 description 11
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 9
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000004071 biological effect Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 8
201000010099 disease Diseases 0.000 description 8
102000004877 Insulin Human genes 0.000 description 7
108090001061 Insulin Proteins 0.000 description 7
229940125396 insulin Drugs 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
150000003573 thiols Chemical group 0.000 description 7
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000003914 insulin secretion Effects 0.000 description 6
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 6
108060001084 Luciferase Proteins 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
229940079593 drug Drugs 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 4
241000282567 Macaca fascicularis Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000009471 action Effects 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
238000000926 separation method Methods 0.000 description 4
230000007812 deficiency Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000243 solution Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108091027981 Response element Proteins 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000002551 irritable bowel syndrome Diseases 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
229920001427 mPEG Polymers 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
229940122199 Insulin secretagogue Drugs 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
238000006845 Michael addition reaction Methods 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241001415846 Procellariidae Species 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
229950010221 alexidine Drugs 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000027455 binding Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000003158 enteroendocrine cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000012921 fluorescence analysis Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
UKVFVQPAANCXIL-FJVFSOETSA-N glp-1 (1-37) amide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 UKVFVQPAANCXIL-FJVFSOETSA-N 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000023187 negative regulation of glucagon secretion Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000029537 positive regulation of insulin secretion Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
229920013730 reactive polymer Polymers 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000003979 response to food Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Polyethers (AREA)

JP2008511371A 2005-05-13 2006-05-11 Ｇｌｐ−１ｐｅｇ化化合物 Expired - Fee Related JP5225074B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US68068805P	2005-05-13	2005-05-13
US60/680,688		2005-05-13
PCT/US2006/018284 WO2006124529A1 (en)	2005-05-13	2006-05-11	Glp-1 pegylated compounds

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2012266820A Division JP2013079256A (ja)	2005-05-13	2012-12-06	Ｇｌｐ−１ｐｅｇ化化合物

Publications (3)

Publication Number	Publication Date
JP2008540565A JP2008540565A (ja)	2008-11-20
JP2008540565A5 JP2008540565A5 (2)	2009-06-25
JP5225074B2 true JP5225074B2 (ja)	2013-07-03

Family

ID=36926842

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2008511371A Expired - Fee Related JP5225074B2 (ja)	2005-05-13	2006-05-11	Ｇｌｐ−１ｐｅｇ化化合物
JP2012266820A Withdrawn JP2013079256A (ja)	2005-05-13	2012-12-06	Ｇｌｐ−１ｐｅｇ化化合物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2012266820A Withdrawn JP2013079256A (ja)	2005-05-13	2012-12-06	Ｇｌｐ−１ｐｅｇ化化合物

Country Status (25)

Country	Link
US (1)	US8183340B2 (2)
EP (1)	EP1881850B1 (2)
JP (2)	JP5225074B2 (2)
KR (1)	KR101011081B1 (2)
CN (1)	CN101166545B (2)
AT (1)	ATE482724T1 (2)
AU (1)	AU2006247734B2 (2)
BR (1)	BRPI0609676A2 (2)
CA (1)	CA2608311C (2)
CY (1)	CY1110853T1 (2)
DE (1)	DE602006017202D1 (2)
DK (1)	DK1881850T3 (2)
EA (1)	EA012442B1 (2)
ES (1)	ES2350852T3 (2)
HR (1)	HRP20100543T1 (2)
IL (1)	IL186772A0 (2)
ME (1)	ME02786B (2)
MX (1)	MX2007014052A (2)
NO (1)	NO20076415L (2)
PL (1)	PL1881850T3 (2)
PT (1)	PT1881850E (2)
RS (1)	RS51637B (2)
SI (1)	SI1881850T1 (2)
UA (1)	UA90896C2 (2)
WO (1)	WO2006124529A1 (2)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8202837B2 (en)	2005-11-04	2012-06-19	Glaxosmithkline Llc	Methods for administering hypoglycemic agents
CA2913805A1 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
EP2364735A3 (en) *	2005-12-16	2012-04-11	Nektar Therapeutics	Branched PEG conjugates of GLP-1
US8501693B2 (en)	2006-08-04	2013-08-06	Amylin Pharmaceuticals, Llc	Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
EP2061767B1 (de)	2006-08-08	2014-12-17	Sanofi	Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
JP2008169195A (ja) *	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
RU2477286C2 (ru)	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
GB2448895A (en) *	2007-05-01	2008-11-05	Activotec Spp Ltd	GLP-1 like compounds and uses thereof
CA2689909C (en)	2007-06-08	2016-04-05	Ascendis Pharma As	Long-acting polymeric prodrugs of exendin
US20110034373A1 (en) *	2007-08-03	2011-02-10	Eli Lilly And Company	Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2010004298A (es)	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
ES2509883T3 (es)	2007-10-30	2014-10-20	Indiana University Research And Technology Corporation	Antagonistas de glucagón
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US20090149673A1 (en) *	2007-12-05	2009-06-11	Semprus Biosciences Corp.	Synthetic non-fouling amino acids
TWI451876B (zh) *	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
CN102105159B (zh)	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
US8450270B2 (en)	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AR072160A1 (es)	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
IT1392655B1 (it) *	2008-11-20	2012-03-16	Bio Ker S R L	Site-specific monoconjugated insulinotropic glp-1 peptides.
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PE20120332A1 (es)	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2443146B1 (en)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
CN101993485B (zh) *	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
KR20120060207A (ko)	2009-08-26	2012-06-11	사노피	신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
JP6006118B2 (ja)	2009-12-16	2016-10-12	ノヴォノルディスクアー／エス	Ｇｌｐ−１アナログ及び誘導体
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
JP5819946B2 (ja) *	2010-05-17	2015-11-24	ベータファーマシューティカルズカンパニーリミテッド	新規のグルカゴン様ペプチド類似体、組成物、および使用方法
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CN102786590A (zh) *	2011-05-19	2012-11-21	江苏豪森药业股份有限公司	分枝型peg修饰的glp-1类似物及其可药用盐
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
KR20140043793A (ko)	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/glp-1 수용체 공동-작용물질
US20130035298A1 (en)	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6374862B2 (ja)	2012-05-24	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
CN102827270A (zh) *	2012-09-13	2012-12-19	无锡和邦生物科技有限公司	一种聚乙二醇化艾塞那肽衍生物及其用途
US20150297573A1 (en)	2012-10-24	2015-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
JP6475233B2 (ja)	2013-06-20	2019-02-27	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
EP3016975B1 (en)	2013-07-04	2019-01-16	Novo Nordisk A/S	Derivatives of glp-1 like peptides, and uses thereof
US10626156B2 (en)	2013-12-06	2020-04-21	Jie Han	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
JP6730278B2 (ja)	2014-11-27	2020-07-29	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
US20160151511A1 (en)	2014-12-02	2016-06-02	Antriabio, Inc.	Proteins and protein conjugates with increased hydrophobicity
WO2016097108A1 (en)	2014-12-17	2016-06-23	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
US10426818B2 (en)	2015-03-24	2019-10-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Method and pharmaceutical composition for use in the treatment of diabetes
WO2016196017A1 (en)	2015-06-04	2016-12-08	Antriabio, Inc.	Amine pegylation methods for the preparation of site-specific protein conjugates
CN106699870A (zh) *	2016-12-14	2017-05-24	江苏师范大学	长效非洲爪蟾胰高血糖素样肽‑1（glp‑1）类似物及其应用
CN107056921B (zh) *	2017-03-23	2020-06-19	桂林八加一药业股份有限公司	一种选择性tnfr1拮抗肽sn10及其在炎症性肠病中的应用
EP3717508A1 (en)	2017-12-01	2020-10-07	The University of Copenhagen	Peptide hormone with one or more o-glycans
AU2019318209B2 (en)	2018-08-10	2025-09-25	Diapin Therapeutics, Llc	Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CN110964116A (zh) *	2018-09-26	2020-04-07	北京辅仁瑞辉生物医药研究院有限公司	GLP1-Fc融合蛋白及其缀合物
CN114478744A (zh) *	2020-11-13	2022-05-13	成都奥达生物科技有限公司	一种长效glp-1拮抗剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
IE50892B1 (en)	1980-02-11	1986-08-06	Novo Industri As	Process for preparing insulin esters
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5445090A (en)	1991-07-25	1995-08-29	Mim Industries, Inc.	Interchangeable clamp for use in a sewing machine
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6214966B1 (en)	1996-09-26	2001-04-10	Shearwater Corporation	Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6448369B1 (en)	1997-11-06	2002-09-10	Shearwater Corporation	Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
JP4078032B2 (ja)	1998-03-12	2008-04-23	ネクターセラピューティックスエイエル，コーポレイション	近位の反応性基を持つポリ（エチレングリコール）誘導体
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
CA2394980C (en)	1999-12-22	2008-05-13	Shearwater Corporation	Sterically hindered derivatives of water soluble polymers
US6413507B1 (en)	1999-12-23	2002-07-02	Shearwater Corporation	Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP4716641B2 (ja) *	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
US6436386B1 (en)	2000-11-14	2002-08-20	Shearwater Corporation	Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
AU2003200839B2 (en) *	2002-01-08	2008-12-11	Eli Lilly And Company	Extended glucagon-like peptide-1 analogs
JP2006520818A (ja) *	2003-03-19	2006-09-14	イーライリリーアンドカンパニー	ポリエチレングリコール結合ｇｌｐ−１化合物
ATE385806T1 (de) *	2003-06-12	2008-03-15	Lilly Co Eli	Fusionsproteine
DK1641823T3 (da) *	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1-analog fusionsproteiner
CN1586625A (zh) *	2004-07-21	2005-03-02	上海第二医科大学附属瑞金医院	用于肿瘤显像和治疗的联合物及其制备方法

2006
- 2006-05-11 CA CA2608311A patent/CA2608311C/en not_active Expired - Fee Related
- 2006-05-11 PT PT06759598T patent/PT1881850E/pt unknown
- 2006-05-11 EA EA200702487A patent/EA012442B1/ru not_active IP Right Cessation
- 2006-05-11 KR KR1020077026259A patent/KR101011081B1/ko not_active Expired - Fee Related
- 2006-05-11 SI SI200630849T patent/SI1881850T1/sl unknown
- 2006-05-11 BR BRPI0609676-0A patent/BRPI0609676A2/pt not_active IP Right Cessation
- 2006-05-11 HR HR20100543T patent/HRP20100543T1/hr unknown
- 2006-05-11 ME MEP-2010-486A patent/ME02786B/me unknown
- 2006-05-11 AT AT06759598T patent/ATE482724T1/de active
- 2006-05-11 PL PL06759598T patent/PL1881850T3/pl unknown
- 2006-05-11 CN CN2006800147033A patent/CN101166545B/zh not_active Expired - Fee Related
- 2006-05-11 RS RS20100486A patent/RS51637B/sr unknown
- 2006-05-11 JP JP2008511371A patent/JP5225074B2/ja not_active Expired - Fee Related
- 2006-05-11 AU AU2006247734A patent/AU2006247734B2/en not_active Ceased
- 2006-05-11 US US11/913,365 patent/US8183340B2/en not_active Expired - Fee Related
- 2006-05-11 EP EP06759598A patent/EP1881850B1/en active Active
- 2006-05-11 DE DE602006017202T patent/DE602006017202D1/de active Active
- 2006-05-11 WO PCT/US2006/018284 patent/WO2006124529A1/en not_active Ceased
- 2006-05-11 MX MX2007014052A patent/MX2007014052A/es active IP Right Grant
- 2006-05-11 DK DK06759598.3T patent/DK1881850T3/da active
- 2006-05-11 ES ES06759598T patent/ES2350852T3/es active Active
- 2006-11-05 UA UAA200712483A patent/UA90896C2/ru unknown
2007
- 2007-10-18 IL IL186772A patent/IL186772A0/en unknown
- 2007-12-12 NO NO20076415A patent/NO20076415L/no not_active Application Discontinuation
2010
- 2010-10-21 CY CY20101100945T patent/CY1110853T1/el unknown
2012
- 2012-12-06 JP JP2012266820A patent/JP2013079256A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ATE482724T1 (de)	2010-10-15
US20090215981A1 (en)	2009-08-27
RS51637B (sr)	2011-10-31
CN101166545A (zh)	2008-04-23
NO20076415L (no)	2007-12-12
EP1881850B1 (en)	2010-09-29
AU2006247734A1 (en)	2006-11-23
CA2608311A1 (en)	2006-11-23
MX2007014052A (es)	2008-02-05
PT1881850E (pt)	2010-11-26
PL1881850T3 (pl)	2011-03-31
US8183340B2 (en)	2012-05-22
SI1881850T1 (sl)	2011-01-31
CA2608311C (en)	2012-11-27
UA90896C2 (en)	2010-06-10
HRP20100543T1 (hr)	2010-11-30
EA012442B1 (ru)	2009-10-30
EP1881850A1 (en)	2008-01-30
ES2350852T3 (es)	2011-01-27
ME02786B (me)	2011-10-31
CY1110853T1 (el)	2012-05-23
KR101011081B1 (ko)	2011-01-25
AU2006247734B2 (en)	2011-06-23
DE602006017202D1 (de)	2010-11-11
IL186772A0 (en)	2008-02-09
WO2006124529A1 (en)	2006-11-23
JP2008540565A (ja)	2008-11-20
JP2013079256A (ja)	2013-05-02
KR20080025361A (ko)	2008-03-20
CN101166545B (zh)	2011-06-15
EA200702487A1 (ru)	2008-04-28
DK1881850T3 (da)	2011-01-03
BRPI0609676A2 (pt)	2011-10-18

Legal Events

Date	Code	Title	Description
2009-05-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090511
2009-05-12	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090511
2011-12-07	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111206
2012-03-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120305
2012-03-13	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120312
2012-04-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120405
2012-04-13	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120412
2012-05-03	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120502
2012-05-14	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120511
2012-06-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120605
2012-06-06	RD03	Notification of appointment of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120605
2012-08-08	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120807
2012-12-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121206
2013-01-30	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130129
2013-02-14	TRDD	Decision of grant or rejection written
2013-02-20	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130219
2013-03-21	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130312
2013-03-22	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2013-03-25	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3
2016-03-22	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5225074B2 (ja)	2013-07-03	Ｇｌｐ−１ｐｅｇ化化合物
CN114901682B (zh)	2024-04-16	胰岛素衍生物
US10159715B2 (en)	2018-12-25	Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
US8501693B2 (en)	2013-08-06	Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
KR101424550B1 (ko)	2014-07-31	지속형 인슐린 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
JP2006520818A5 (2)	2010-09-24
JP2006520818A (ja)	2006-09-14	ポリエチレングリコール結合ｇｌｐ−１化合物
US20090238838A1 (en)	2009-09-24	Insulinotropic peptide conjugate using an immunoglobulin fc
TW201733613A (zh)	2017-10-01	用於治療肥胖之升糖素及glp-1共促效劑
JP2024546026A (ja)	2024-12-17	Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用
CN118574842A (zh)	2024-08-30	酰化胰岛素
JP2011503019A (ja)	2011-01-27	薬学的使用のための新規のニュールツリン複合体
HK1117054A (en)	2009-01-09	Glp-1 pegylated compounds
WO2015057908A1 (en)	2015-04-23	Methods of treating diabetes and related disorders
HK1230958A1 (en)	2017-12-15	Composition for treating diabetes, containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate